Sunday, May 26, 2019
MZ Digital Marketing Agency
from Reuters: Health News https://reut.rs/2Mb59GM
Sunday, May 26, 2019
Sunday, May 26, 2019
MZ Digital Marketing Agency
HEALTH NEWS
No comments
Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.
from Reuters: Health News https://reut.rs/2Mb59GM
from Reuters: Health News https://reut.rs/2Mb59GM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment